Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
|Articles|June 1, 2009
- ONCOLOGY Nurse Edition Vol 23 No 4
- Volume 23
- Issue 4
ONCOLOGY Nurse Edition April 2009, Vol 23 No 4
Advertisement
Main Articles
PALLIATIVE CARE SERIES: When Hospice Is the Best Option: An Opportunity to Redefine Goals
Reviewed in: Reviewed in: The Prince-Paul Article Reviewed: Improving the End-of-Life Experience
Departments
Patient Information
- Understanding and Managing Nausea and Vomiting
Articles in this issue
over 17 years ago
Hypertension Management in the Era of Targeted Therapies for Cancerover 17 years ago
An Alkylating Agent for CLL and NHLover 17 years ago
Vesicant Extravasation From an Implanted Venous Access Portover 17 years ago
Survivorship Care: Essential Components and Models of Deliveryover 17 years ago
Cardiotoxicities of Breast Cancer Treatmentover 17 years ago
Improving the End-of-Life Experienceover 17 years ago
When Hospice Is the Best Option: An Opportunity to Redefine Goalsover 17 years ago
Living Well: A Goal for All Patientsover 17 years ago
The Patient With Cancer-Related DyspneaAdvertisement
Related to this article
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5